Clearmind Medicine (Nasdaq: CMND) signs LOI for 51% EV charging stake

Rhea-AI Filing Summary

Clearmind Medicine Inc. entered into a non-binding Letter of Intent to acquire a 51% majority stake in a company that provides intelligent wireless charging solutions for electric vehicles in automated parking systems and autonomous mobile platforms.

Under the LOI, Clearmind will acquire this stake for an aggregate purchase price of $2.5 million. As a condition to closing, Clearmind will extend a $1.5 million loan to the target company, bearing 4% annual interest and repayable two years after closing. Completion is subject to definitive agreements, final due diligence and other closing conditions. Clearmind remains primarily a clinical-stage biotech focused on non-hallucinogenic, neuroplastogen-derived therapeutics and holds nineteen patent families, including 32 granted patents.

Key Figures

Stake to be acquired: 51% Acquisition purchase price: $2.5 million Loan principal: $1.5 million +4 more

7 metrics

Stake to be acquired 51% Majority equity interest in the EV wireless charging company under the LOI

Acquisition purchase price $2.5 million Aggregate consideration for the 51% majority stake

Loan principal $1.5 million Loan Clearmind will extend to the acquired company as a condition to closing

Loan interest rate 4% per annum Interest rate on the $1.5 million loan, repayable two years after closing

Charging power 10 kW Maximum continuous wireless charging capability of the target’s system

Patent families 19 Number of Clearmind’s intellectual property patent families

Granted patents 32 Granted patents in Clearmind’s IP portfolio

Key Terms

Letter of Intent, non-binding, neuroplastogen-derived therapeutics, automated parking systems, +1 more

5 terms

Letter of Intent regulatory

"announced that it has entered into a non-binding Letter of Intent"

A letter of intent is a document that shows an agreement in principle between parties to work towards a future deal or transaction. It outlines their intentions and key terms, acting like a roadmap before a formal contract is signed. For investors, it signals serious interest and helps clarify expectations early in the process.

non-binding regulatory

"announced that it has entered into a non-binding Letter of Intent"

"Non-binding" describes an agreement or statement that does not legally require the parties involved to follow through with its terms. It’s like a handshake or a written promise that shows intent but isn’t enforceable by law. For investors, understanding whether an agreement is binding or non-binding helps gauge how seriously the parties are committed and how much weight to give to the promises made.

neuroplastogen-derived therapeutics medical

"development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics"

Neuroplastogen-derived therapeutics are drugs or biological treatments developed from compounds that promote neuroplasticity — the brain’s ability to rewire and form new connections after injury or in response to learning. For investors, they matter because these therapies target underlying brain repair mechanisms rather than only masking symptoms, offering the potential for durable benefits in conditions like depression, stroke recovery, or neurodegeneration; if effective, they can create large, high-value markets similar to replacing a faulty bridge with a stronger one.

automated parking systems technical

"wireless charging solutions for automated parking systems and autonomous mobile platforms"

forward-looking statements regulatory

"This press release contains “forward-looking statements” within the meaning"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/03/2026 - 08:12 AM Accepted by SEC EDGAR 08/03/2026 - 08:12 AM Learn about SEC filing dates

FAQ

What transaction did Clearmind Medicine (CMND) disclose in its August 2026 Form 6-K?

Clearmind Medicine disclosed a non-binding Letter of Intent to acquire a 51% majority stake in a company providing intelligent EV wireless charging solutions for automated parking systems and autonomous mobile platforms.

What are the financial terms of Clearmind Medicine’s (CMND) proposed 51% acquisition?

Clearmind plans to pay an aggregate purchase price of $2.5 million for the 51% stake. In addition, it will provide a $1.5 million loan to the acquired company as a condition to closing.

What are the key terms of the loan Clearmind Medicine (CMND) will extend to the acquired company?

Clearmind will extend a $1.5 million loan bearing 4% annual interest. The loan is scheduled to be repaid on the two-year anniversary of the acquisition closing, and is a condition to completing the transaction.

Is Clearmind Medicine’s (CMND) acquisition of the EV charging company definitive?

No. The agreement is currently a non-binding Letter of Intent. Closing remains subject to signing definitive agreements, completing final due diligence, and satisfying specified closing conditions.

What does the target company in Clearmind Medicine’s (CMND) LOI specialize in?

The target company develops intelligent wireless charging solutions for automated parking systems and autonomous mobile platforms, using proprietary technology with smart communication, dynamic energy management, and continuous charging up to 10 kW without cables or manual connections.

What is Clearmind Medicine’s (CMND) core business and IP position?

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech developing non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics. Its intellectual property portfolio includes nineteen patent families and 32 granted patents as of the latest disclosure.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: August 2026

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on August 3, 2026, titled “Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company”.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: August 3, 2026	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3

Exhibit 99.1

Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company

Vancouver, Canada, August 3, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has entered into a non-binding Letter of Intent (“LOI”) to acquire 51% stake in a leading intelligent EV (electric vehicles) wireless charging solutions for automated parking systems and autonomous mobile platforms company (the “Acquired Company”).

The Acquired Company develops intelligent wireless charging solutions for automated parking systems and autonomous mobile platforms. Based on proprietary technology featuring smart communication, dynamic energy management, and continuous charging up to 10 kW, the system requires no cables, no manual connections, or traditional charging infrastructure. It integrates seamlessly with robotic parking systems while enabling real-time energy management. As one of the few companies worldwide commercially deploying dedicated wireless charging for automated parking - and among the first of its kind - the technology is designed to advance smart parking infrastructure, autonomous vehicles, and future urban environments by significantly improving operational efficiency, safety, and user experience.

Under the terms of the LOI, Clearmind will acquire the majority stake of the Acquired Company for an aggregate purchase price of $2.5 million (the “Acquisition”). In addition, in connection with and as a condition to the closing of the Acquisition (the “Closing”), the Company shall extend a loan to the Acquired Company in the principal amount of $1.5 million (the “Loan”). The Loan shall bear interest at a rate of 4% per annum and shall be repaid on the two year anniversary of the Closing.

The Closing of the Acquisition is subject to the execution of definitive agreements, final due diligence and the satisfaction of certain closing conditions.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations

invest@clearmindmedicine.com

www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the signing of definitive agreements for the acquisition of the Acquired Company, the timing and completion of the acquisition, and the satisfaction of closing conditions related to the acquisition. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE TITLED: "CLEARMIND MEDICINE SIGNS LETTER OF INTENT TO ACQUIRE 51% 13.2 KB